Background
Methods
Search strategy
Inclusion criteria and data extraction
Study evaluation
Quality criteria were defined according to study design
-
HRQoL was identified as primary or secondary outcome in the abstract (for studies with more than one outcome parameter),
-
there was an a priori hypothesis concerning HRQoL (not applicable if explorative),
-
an explicit rationale for HRQoL instrument selection was provided,
-
the instrument was validated or psychometric properties were reported or referenced,
-
the HRQoL instrument was cancer-specific,
-
the instrument administration was reported,
-
missing data was documented or discussed,
-
statistical considerations for dealing with missing data were provided,
-
reports on HRQoL results were complete and scoring was correct,
-
the issue of clinical significance had been addressed.
-
compliance was reported.
-
baseline compliance was documented,
-
the timing of assessment was reported.
-
statistical power or effect sizes for HRQoL results were reported.
-
HRQoL results were considered in discussion section.
Results
Study selection and study characteristics
Author, year | Sample size, diagnosis (disease severity) | Treatment modality/intervention | Comparison | PRO primary outcome | HRQoL measure |
---|---|---|---|---|---|
Randomised controlled trials | |||||
Arnold et al., 2005 [52] |
N = 109, foregut, midgut NET, CUP (locally advanced, metastatic) | octreotide | octreotide + INT | no | QLQ-C30 |
Bajetta et al., 2006 [53] |
N = 60, well-differentiated intestinal, pancreatic, bronchial NET, other, CUP (low-grade malignancy) | lan ATG | lan MP | no | QLQ-C30 |
Caplin et al., 2014 [42] (CLARINET)
|
N = 204, well- or moderately differentiated pancreatic, midgut, hindgut NET, other, CUP (progressive, metastatic) | lan ATG | placebo | no | QLQ-C30, QLQ-GI.NET21 |
Jacobsen & Hanssen, 1995 [54] |
N = 11, intestinal NET, PNET (liver metastases) | octreotide | placebo (cross-over design) | no | GHQ-30, PAIS |
Meyer et al., 2014 [55] |
N = 86, PNET, GI foregut NET, CUP (advanced, metastatic) | capecitabine + streptozocin + cisplatine | capecitabine + streptozocin | no | QLQ-C30 |
Raymond et al., 2011 [56] |
N = 171, well-differentiated PNET (advanced, metastatic) | sunitinib | placebo | no | QLQ-C30 |
Rinke et al., 2009 [57] (PROMID)
|
N = 85, well-differentiated midgut NET (metastatic) | octreotide LAR | placebo | no | QLQ-C30 |
Yao et al., 2016 [45] (RADIANT-4)
|
N = 302, well-differentiated GI-NET, bronchopulmonary NET (advanced, progressive) | everolimus | placebo | no | FACT-G |
Phase II studies | |||||
Bodei et al., 2011 [58] |
N = 51, bronchial, pancreatic, duodenal, ileal, appendicular, sigma-rectal NET, CUP (progressive, other) |
177Lu-DOTATATE | - | no | QLQ-C30 |
Bushnell et al., 2010 [59] |
N = 90, carcinoid (metastatic, refractory to octreotide) |
90Y-DOTADOC | - | no | EQ-5D |
Claringbold et al., 2011 [60] |
N = 33, well-differentiated NET (progressive) |
177Lu-DOTATATE | - | no | QLQ-C30 |
Cwikla et al., 2010 [61] |
N = 60, GEP-NET (progressive, metastatic) |
90Y-DOTATATE | - | no | QLQ-C30, QLQ-GI.NET21 |
Delpassand et al., 2014 [62] |
N = 37, GEP-NET (progressive) |
177Lu-DOTATATE | - | no | QLQ-C30 |
Ducreux et al., 2014 [43]; Mitry et al., 2014 [44] (BETTER)
|
N = 34, well-differentiated PNET (progressive, metastatic)
N = 49, well-differentiated GI-NET (progressive, metastatic) | bevacizumab + 5-FU/streptozocin; bevacizumab + capecitabine | - | no | QLQ-C30 |
Frilling et al., 2006 [63] |
N = 18, ileal, pancreatic NET, paraganglioma, gastrinoma, CUP (progressive, metastatic) |
90Y-DOTATOC; 177Lu-DOTATOC | - | no | SF-36 |
Khan et al., 2011 [64] |
N = 256, carcinoid, PNET, CUP, gastrinoma, glucagonoma, insulinoma, VIPoma (with and without metastases) |
177Lu-DOTATATE | - | yes | QLQ-C30 |
Korse et al., 2009 [65] |
N = 39, GI-NET (advanced, metastatic) | octreotide LAR | - | no | QLQ-C30 |
Kulke et al., 2008 [66] |
N = 107, carcinoid, PNET (advanced) | sunitinib | - | no | EQ-5D, FACIT-Fatigue scale |
Kvols et al., 2012 [67] |
N = 45, GI-NET (advanced, metastatic) | pasireotide | - | no | FACIT-D |
Martin-Richard et al., 2013 [68] |
N = 30, well-differentiated GEP-NET, bronchopulmonary NET, CUP (progressive) | lan ATG | - | no | QLQ-C30 |
Ruszniewski et al., 2004 [69] |
N = 71, foregut, midgut, hindgut NET, other (not terminally ill) | lan PR | - | no | QLQ-C30 |
Wymenga et al., 1999 [70] |
N = 55, carcinoid, gastrinoma, VIPoma (tumour stages III and IV) | lan PR | - | no | QLQ-C30 |
Zuetenhorst et al., 2004 [71] |
N = 26, well-differentiated ileo-cecal, gastric, bronchopulmonary NET, CUP (metastatic) | INT followed by unlabelled MIBG followed by 131I-MIBG | - | no | QLQ-C30 |
Prospective studies | |||||
Fröjd et al., 2007 [72]; Fröjd et al., 2009 [73] |
N = 36, carcinoid (metastatic, other) | INT; octreotide; INT + octreotide; CTX; octreotide + CTX; no treatment | normative data (subsample) | yes | QLQ-C30 |
Haugland et al., 2013 [74] |
N = 37, GI-NET (not terminally ill) | medical treatment (n.s.) | - | yes | SF-36 |
Kalinowski et al., 2009 [75] |
N = 9, bronchial, jejunal, ileal, gastric NET, PNET, insulinoma (liver metastases) |
90Y microspheres | - | no | QLQ-C30, QLQ-LMC21 |
Kwekkeboom et al., 2003 [76] |
N = 35, GEP-NET (progressive, other) |
177Lu-DOTATATE | - | no | QLQ-C30 |
Larsson & Janson, 2008 [77] |
N = 18, midgut carcinoid (n.s.) | INT | - | yes | QLQ-C30, FACT-An |
Larsson et al., 2001 [78] |
N = 24, midgut carcinoid (metastatic, other) | INT; SSA; INT + SSA | normative data | yes | QLQ-C30 |
O’Toole et al., 2000 [79] |
N = 33, intestinal NET, PNET, other (metastatic) | octreotide followed by lanreotide | lanreotide followed by octreotide | no | ISPN |
Pasieka et al., 2004 [80] |
N = 24, small bowel carcinoid, medullary thyroid cancer, CUP (progressive, metastatic) |
131I-MIBG; 111In-octreotide | - | no | ad hoc questionnaire |
Spolverato et al., 2015 [81] |
N = 85, intestinal, pancreatic, bronchial NET, CUP (neuroendocrine liver metastasis) | surgical vs. nonsurgical treatment | - | yes | self-constructed questionnaire |
Teunissen et al., 2004 [82] |
N = 50, carcinoid, PNET, CUP, gastrinoma, insulinoma (metastatic) |
177Lu-DOTATATE | - | yes | QLQ-C30 |
Cross-sectional studies | |||||
Beaumont et al., 2012 [83]; |
N = 663, carcinoid, islet cell, “do not know or not sure which type” (local, regional, distant, currently not present) | surgery; surgery + SSA; other; no past/current treatment | normative data | yes | SF-36, PROMIS global health short form, PROMIS-29 |
Pearman et al., 2016 [84] | - | ||||
Gelhorn et al., 2016 [85] |
N = 11, midgut, hindgut NET (metastatic) | telotristat etiprate | normative data | yes | QLQ-C30, QLQ-GI.NET21 |
Haugland et al., 2009 [86] |
N = 96, GI-NET (not terminally ill) | INT; SSA; INT + SSA; CTX; no treatment | normative data | yes | SF-36 |
Haugland et al., 2016 [87] |
N = 196, GI-NET (not terminally ill) | medical treatment (n.s.) | normative data | yes | SF-36 |
Larsson et al., 1998 [88] |
N = 17, carcinoid, PNET (not terminally ill) (+ staff, N = 17) | INT; SSA; INT + SSA | - | yes | QLQ-C30 |
Larsson, Sjöden et al., 1999 [89] |
N = 119, carcinoid, PNET (n.s.) | INT + octreotid; INT; octreotide; CTX; XTR; omeprazol; no treatment | - | yes | QLQ-C30 |
Larsson, von Essen et al., 1999 [90] |
N = 99, carcinoid, PNET (not terminally ill) | INT; SSA; INT + SSA | - | yes | QLQ-C30 |
Larsson et al., 2003 [91] |
N = 19, carcinoid (n.s.) (+ staff, N = 19) | INT; SSA; INT + SSA | - | yes | semi-structured interviews |
Larsson et al., 2007 [92] |
N = 83, carcinoid, PNET (n.s.) | INT/octreotide; CTX; XTR; omeprazol; no treatment | - | yes | QLQ-C30 |
Petzel et al., 2012 [93] |
N = 240, PNET, periampullary neoplasms (disease-free after surgery) | no current treatment | - | yes | FACT-Hep |
Pezzilli et al., 2009 [94] |
N = 44 PNET (disease free, advanced) | SSA; SSA + other; no treatment | normative data | yes | SF-12, GHQ-12 |
Pezzilli et al., 2010 [95] |
N = 44 ileal NET (disease free, advanced) | SSA; INT; CTX; SSA + other; no treatment | yes | SF-12 | |
Ruszniewski et al., 2016 [96] (SYMNET)
|
N = 273, small bowel carcinoid, appendicular, colonic, bronchopulmonary NET, CUP (92 % with metastases) | lan ATG | - | yes | QLQ-C30, QLQ-GI.NET |
van der Horst-Schrivers et al., 2009 [97] |
N = 43, midgut NET (metastatic) | SSA; INT; SSA + INT | normative data | yes | QLQ-C30 |
von Essen et al., 2002 [98] |
N = 85, GI-NET (n.s.) | INT; SSA; INT + SSA | - | yes | QLQ-C30 |
Grey literature | |||||
Garcia-Hernandez et al., 2012 [99] |
N = 74, GI-NET (n.a.) | n.a. | - | yes | QLQ-C30, QLQ-GI.NET21 |
Gyökeres et al., 2010 [100] |
N = 93, GI-NET (59 % with metastases) | SSA | - | yes | QLQ-C30, QLQ-GI.NET21 |
Marinova et al., 2016 [101] |
N = 68, PNET (n.a.) | PRRT (n.s.) | - | yes | QLQ-C30 |
Pavel et al., 2013 [102] |
N = 126, PNET (advanced) | everolimus | - | no | QLQ-C30, QLQ-GI.NET21 |
Strosberg et al., 2015 [103] |
N = 230, midgut NET (advanced, progressive, metastatic) |
177Lu-DOTATATE | octreotide LAR | no | QLQ-C30, QLQ-GI.NET21 |
Applied instruments for measuring health-related quality of life
Evaluation of methodological quality of HRQoL reporting
Author, year | HRQoL stated as prim./sec. aima
| A priori hypothesis | Instrument rational | Instrument validationb
| Cancer-specific instrument | Instrument administration | (Baseline) compliance | Timing of assessments | Missing data reported | Statistical methods for missing data | Power or effect sizes (HRQoL) | Presentation of results adequatec
| Clinical significance addressed | HRQoL results discussed |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Randomised controlled trials | ||||||||||||||
Arnold et al., 2005 [52] | - | - | + | + | + | - | + | + | + | - | - | - | - | + |
Bajetta et al., 2006 [53] | - | - | - | + | + | + | - | + | + | + | - | - | - | + |
Caplin et al., 2014 [42] (CLARINET)
| + | - | - | + | + | - | - | + | + | + | - | + | - | - |
Jacobsen & Hanssen, 1995 [54] | + | - | - | + | -d
| - | + | + | + | - | - | - | + | + |
Meyer et al., 2014 [55] | + | - | - | + | + | - | + | + | + | - | - | - | - | - |
Raymond et al., 2011 [56] | - | - | - | + | + | + | - | + | + | - | - | - | + | + |
Rinke et al., 2009 [57] (PROMID)
| - | - | - | + | + | - | + | + | - | - | - | - | - | - |
Yao et al., 2016 [45] (RADIANT-4)
| - | - | + | + | + | + | + | + | - | + | - | n.r. | + | n.r. |
Phase II studies | ||||||||||||||
Bodei et al., 2011 [58] | - | - | - | + | + | - | - | + | - | - | - | - | - | + |
Bushnell et al., 2010 [59] | - | - | - | + | - | - | + | + | + | - | - | - | - | - |
Claringbold et al., 2011 [60] | - | - | - | + | + | - | - | + | + | - | - | - | - | + |
Cwikla et al., 2010 [61] | - | - | - | + | + | + | - | + | + | - | - | - | - | - |
Delpassand et al., 2014 [62] | - | - | - | + | + | - | - | + | + | - | - | - | - | - |
Ducreux et al., 2014 [43]; Mitry et al., 2014 [44] (BETTER)
| + | - | - | + | + | - | - | + | + | - | - | - | - | - |
Frilling et al., 2006 [63] | - | - | - | + | - | - | - | + | + | - | - | - | - | - |
Khan et al., 2011 [64] | N/A | - | + | + | + | + | + | + | + | - | - | - | + | + |
Korse et al., 2009 [65] | N/A | - | + | + | +d
| - | - | - | + | - | - | - | - | N/A |
Kulke et al., 2008 [66] | - | - | - | + | - | + | - | + | + | - | - | - | - | + |
Kvols et al., 2012 [67] | - | - | - | + | + | - | - | + | + | - | - | - | - | + |
Martin-Richard et al., 2013 [68] | + | - | - | + | + | - | - | + | - | - | - | + | - | - |
Ruszniewski et al., 2004 [69] | - | - | - | + | + | - | + | + | + | - | - | - | - | + |
Wymenga et al., 1999 [70] | - | - | - | + | + | - | - | + | - | + | - | + | - | + |
Zuetenhorst et al., 2004 [71] | - | + | - | + | +d
| - | - | + | + | - | - | - | - | + |
Prospective studies | ||||||||||||||
Fröjd et al., 2007 [72]; Fröjd et al., 2009 [73] | N/A | N/A | - | + | +d
| + | + | + | + | + | - | + | + | N/A |
Haugland et al., 2013 [74] | N/A | - | - | + | - | + | + | + | + | + | + | + | - | N/A |
Kalinowski et al., 2009 [75] | - | - | + | + | + | - | - | + | - | - | - | - | - | + |
Kwekkeboom et al., 2003 [76] | - | - | - | + | + | + | - | + | + | - | - | - | - | + |
Larsson & Janson, 2008 [77] | N/A | N/A | + | + | + | - | - | + | + | - | - | + | + | N/A |
Larsson et al., 2001 [78] | N/A | - | - | + | +d
| + | + | + | + | - | - | + | + | N/A |
O’Toole et al., 2000 [79] | - | + | - | + | -d
| + | - | + | - | - | - | + | - | + |
Pasieka et al., 2004 [80] | - | - | - | - | - | + | + | + | + | - | - | - | + | + |
Spolverato et al., 2015 [81] | N/A | + | + | - | + | + | + | + | + | - | - | - | - | N/A |
Teunissen et al., 2004 [82] | N/A | N/A | + | + | + | + | - | + | + | + | - | + | + | N/A |
Cross-sectional studies | ||||||||||||||
Beaumont et al., 2012 [83]; | N/A | N/A | - | + | - | + | + | N/A | + | - | + | + | + | N/A |
Pearman et al., 2016 [84] | - | |||||||||||||
Gelhorn et al., 2016 [85] | - | N/A | - | + | + | + | + | N/A | + | - | N/A | - | + | + |
Haugland et al., 2009 [86] | N/A | N/A | + | + | - | + | + | N/A | + | - | + | + | + | N/A |
Haugland et al., 2016 [87] | N/A | + | - | + | - | + | + | N/A | + | + | - | - | - | N/A |
Larsson et al., 1998 [88] | N/A | N/A | + | + | +d
| + | + | N/A | + | - | N/A | - | - | N/A |
Larsson, Sjöden et al., 1999 [89] | N/A | N/A | + | + | + | + | - | N/A | + | - | N/A | + | + | N/A |
Larsson, von Essen et al., 1999 [90] | N/A | N/A | + | + | +d
| + | + | N/A | + | - | N/A | + | + | N/A |
Larsson et al., 2003 [91] | N/A | N/A | N/A | N/A | N/A | + | - | N/A | + | N/A | N/A | N/A | N/A | N/A |
Larsson et al., 2007 [92] | N/A | N/A | + | + | +d
| + | + | N/A | + | - | N/A | + | - | N/A |
Petzel et al., 2012 [93] | N/A | + | + | + | + | + | - | N/A | + | + | N/A | + | - | N/A |
Pezzilli et al., 2009 [94] | N/A | - | - | + | - | + | + | N/A | + | - | - | - | - | N/A |
Pezzilli et al., 2010 [95] | N/A | - | - | + | - | + | - | N/A | - | - | - | - | - | N/A |
Ruszniewski et al., 2016 [96] (SYMNET)
| - | N/A | - | + | + | + | - | N/A | - | + | + | - | - | + |
van der Horst-Schrivers et al., 2009 [97] | N/A | N/A | - | + | + | + | + | N/A | - | - | - | + | - | N/A |
von Essen et al., 2002 [98] | N/A | N/A | - | + | + | + | + | N/A | + | - | - | - | - | N/A |